

Supplementary Material for

Considering tumour sidedness is critical for accurate interpretation of liquid biopsy results in metastatic colorectal cancer

Marta Toledano-Fonseca^{1,2,3†}, Icíar de la Fuente^{1,4†}, María José Ortiz-Morales⁴, Pablo Cano-Ramírez^{1,2}, Gema Pulido-Cortijo⁴, María Teresa Cano-Osuna⁴, María Victoria García-Ortiz^{1,2,4}, María Auxiliadora Gómez-España^{1,2,3,4}, Antonio Rodríguez-Ariza^{1,2,4*} and Enrique Aranda^{1,2,3,4}

¹ University of Córdoba/ Maimonides Biomedical Research Institute of Cordoba (IMIBIC) / Reina Sofia University Hospital, Córdoba, Spain

² Cancer Network Biomedical Research Center (CIBERONC), Madrid, Spain

³ Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba, Spain

⁴ Medical Oncology Department, Reina Sofia University Hospital, Córdoba, Spain

[†]These authors contributed equally to this work and share first authorship

*Corresponding author: antonio.rodriquez.exts@juntadeandalucia.es

Supplementary Table 1. Prognostic impact of clinical characteristics.

OS			PFS	
	HR (95%CI)	<i>p value</i>	HR (95%CI)	<i>p value</i>
RAS mutation status plasma				
WT	1.44(1.09-1.94)	0.0117^a	1.31 (1.00-1.74)	0.0521
MUT ^R				
cfDNA concentration (ng/ml)				
≤37.6 ^R	0.51 (0.34-0.68)	<0.0001	0.75 (0.53-1.04)	0.0861
>37.6				
cfDNA fragmentation (%)				
≤31.055 ^R	0.79 (0.47-1.31)	0.3624	1.045 (0.639-1.715)	0.8586
>31.055				
cfDNA fragment size (bp)				
<137	1.80 (1.03-3.82)	0.0441	1.30 (0.73-2.46)	0.3566
>137				
MAF (%)				
≤1.209 ^R	0.55 (0.39-0.85)	0.0062	0.99 (0.65-1.52)	0.9723
>1.209				
CEA (U/ml)				
≤46.8 ^R	0.68 (0.49-0.94)	0.0192	0.89 (0.65-1.21)	0.4523
>46.8				

^R Reference category for analysis; ^a Statistical significant *p* values are indicated in bold